# Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes

> **NCT03132181** · PHASE2 · COMPLETED · sponsor: **RWTH Aachen University** · enrollment: 40 (actual)

## Conditions studied

- Diabetes Mellitus Type 2 (T2DM)

## Interventions

- **DRUG:** Empagliflozin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03132181
- **Lead sponsor:** RWTH Aachen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-24
- **Primary completion:** 2019-01-23
- **Final completion:** 2019-01-23
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03132181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03132181, "Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03132181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*